The FINANCIAL — GE Healthcare, the healthcare division of General Electric Company is working to help physicians potentially improve patient care throughout the breast cancer journey through one of the most comprehensive portfolios of technologies in the industry available today.
While at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS 2012), taking place in San Antonio from December 5-7, GE Healthcare will provide attendees with an overview of its innovative breast cancer solutions for healthcare practitioners. As General Electronics said, these innovations, which range from screening to diagnosis, then to staging, treatment planning and monitoring, recently received Frost & Sullivan's 2012 breast imaging product line strategy award for North America for having the most comprehensive portfolio and may have a transformational impact on breast cancer care delivery.
Visitors to the GE Healthcare booth at SABCS 2012 will also be able to speak with GE Healthcare experts and executives about its commitment to innovative patient-focused solutions. GE Healthcare is also sponsoring a presentation and panel discussion entitled “Enabling More Confident Decisions for Breast Cancer Treatment” on Thursday, December 6 at 2:00pm at the Product Theatre in the Exhibit Hall of the Henry B. Gonzalez Convention Center. Speakers and topics include:
Mammostrat – A Breast Cancer Recurrence Assay – Tamoxifen versus Exemestane Adjuvant Multicenter (TEAM) Trial Update – John M.S. Bartlett, MD, Director of Transformative Pathology at Ontario Institute of Cancer Research, Toronto, Ontario, Canada
Discordance in HER2 Testing in Metastatic Breast Cancer – VIRGO Trial Update – Edith Perez, MD, Deputy Director at Large, Mayo Clinic Cancer Center
New Updates and Advances in Ductal Carcinoma In Situ (DCIS) – Craig Allred, MD, Professor, Department of Pathology, Washington University School of Medicine
Additionally, results from three GE Healthcare-sponsored studies will be presented at SABCS 2012:
Presentation P2-10-04 -The Mammostrat Test is an Effective Tool to Stratify Patient Samples Previously Characterized as Intermediate by the Oncotype Dx Test – Thursday, December 6, 7:00 – 9:00am, Hall A-B
Presentation P3-05-05 – HER2 Expression and Gene copy analysis by Immunofluorescence and Fluorescence in situ Hybridization, on a Single formalin-fixed paraffin-embedded tissue section – Thursday, December 6, 5:00-7:00pm, Hall A-B
Presentation P3-05-06 – Automated Analysis of Her2 FISH Using Combined Immunofluorescence and FISH Signals – Thursday, December 6, 5:00-7:00pm, Hall A-B
“With a disease as complex and multi-faceted as breast cancer, innovations need to be equally multi-faceted and even more integrated in their scope, and GE Healthcare is fully committed to developing solutions that enable physicians to improve the quality of care provided to the patients they treat,” said Carrie Eglinton-Manner, CEO, Clarient Diagnostic Services, a GE Healthcare company. “The studies presented at SABCS in addition to the information being shared at the product theater are further demonstration of that commitment.”
Discussion about this post